Marginal Corneal Infiltration Following Treatment for Metastatic Breast Cancer with Triple Chemotherapy of Trastuzumab, Pertuzumab &amp; Docetaxel

Kafa, Ghyath; Horani, Mania; Musa, Fayyaz; Al-Husban, Ahmad; Hegab, Mohamed; Asir, Noor

doi:10.1080/09273948.2022.2027460

Cited by 7 publications

(4 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…First of all, our patient was previously treated with paclitaxel. Corneal epithelial lesions and limbal stem-cell deficiency during paclitaxel treatment have been described previously [12] . However, in our patient, paclitaxel was discontinued 1 month before the first signs of corneal toxicity.…”

Section: Discussionmentioning

confidence: 98%

See 1 more Smart Citation

A Case of Corneal Melting in a Patient with HER2-Positive Breast Cancer

Peeters¹,

Vereecken²,

Denys³

et al. 2022

Case Rep Ophthalmol

View full text Add to dashboard Cite

Trastuzumab is the cornerstone treatment for HER2-positive breast cancer. While ocular side effects are more commonly described after the use of the antibody-drug conjugate ado-trastuzumab emtansine, we here describe corneal melting in a 79-year-old patient after three cycles of trastuzumab monotherapy. Signs and symptoms persisted with subsequent trastuzumab cycles. The patient showed improvement after treatment with intense lubrication, topical antibiotics, and topical steroids. After tapering of steroids, there was recurrence of epitheliopathy after subsequent trastuzumab treatment, which subsided upon restarting topical steroids. Finally, the patient was kept on a low-dose topical steroid regimen which prevented further epitheliopathy during the next trastuzumab cycles.

show abstract

Section: Discussionmentioning

confidence: 98%

“…Alternatively, the corneal damage could be immunologically mediated by antibody-dependent cell cytotoxicity. Recently, Kafa et al [12] published a case of bilateral marginal corneal infiltration upon combined treatment with trastuzumab, pertuzumab, and docetaxel.…”

Section: Discussionmentioning

confidence: 99%

A Case of Corneal Melting in a Patient with HER2-Positive Breast Cancer

Peeters¹,

Vereecken²,

Denys³

et al. 2022

Case Rep Ophthalmol

View full text Add to dashboard Cite

show abstract

“…Previous studies have shown that BMS-754807, as an inhibitor of IGF1R/IR, may be used in the treatment of gliomas and SKCM [32,33]. Of note, docetaxel is used in the treatment of PRAD, BRCA, and LUAD [34][35][36]. There is a negative correlation between temozolomide and IL4I1 expression, and temozolomide is commonly utilized as a chemotherapeutic drug in patients with gliomas [37].…”

Section: Discussionmentioning

confidence: 99%

Pan-cancer analysis of prognostic and immunological role of IL4I1 in human tumors: a bulk omics research and single cell sequencing validation

Chen,

Liu,

et al. 2024

Discov Onc

View full text Add to dashboard Cite

Background Interleukin-4 inducible gene 1 (IL4I1) regulates tumor progression in numerous tumor types. However, its correlation with immune infiltration and prognosis of patients in a pan-cancer setting remains unclear. Methods Data from the Cancer Genome Atlas (TCGA), Genotype-Tissue Expression (GTEx), UALCAN, Clinical Proteomic Tumor Analysis Consortium (CPTAC), Gene Expression Omnibus (GEO), cBioPortal, Cancer Single-cell State Atlas (CancerSEA), and Tumor IMmune Estimation Resource(TIMER) databases were used to evaluate IL4I1 expression, clinical features and prognostic effects, gene set enrichment, and correlation with immune cell infiltration, as well as the relationship between IL4I1 methylation and expression and survival prognosis. Correlations with 192 anticancer drugs were also analyzed. Results IL4I1 was significantly overexpressed in the majority of tumors, and the imbalance of IL4I1 was significantly correlated with overall survival and pathological stage. Moreover, total IL4I1 protein was increased in cancer. Therefore, IL4I1 may be used as a prognostic biomarker or protective factor in numerous types of cancer. The methylation level of IL4I1 may also be used as a prognostic marker. The functional enrichment of IL4I1 was closely related to the immunomodulatory pathway. In addition, the level of tumor-associated macrophage infiltration was positively correlated with the expression of IL4I1 in pan-cancerous tissues. scRNA-seq analysis suggested that IL4I1 differ significantly among different cells in the tumor microenvironment and was most enriched in macrophages. Various immune checkpoint genes were positively correlated with IL4I1 expression in most tumors. In addition, patients with high IL4I1 expression may be resistant to BMS-754807 and docetaxel, but sensitive to temozolomide. Conclusion IL4I1 may play a role as promoter of cancer and prognostic indicator in patients. High expression of IL4I1 is associated with the state of tumor immunosuppression and may contribute to tumor-associated macrophage invasion. Therefore, IL4I1 may be a new therapeutic target for the treatment and prognosis of patients with cancer.

show abstract

“…Long-term use of topical glaucoma medications is known to be associated with ophthalmic complications, in particular ocular surface toxicity, most often due to the nature of the preservatives included in the medications [1,2]. The ocular surface is vulnerable also to other drugs and preservatives, traumatic injuries, microorganisms, dry eye and immuno-allergic reactions [3]. Furthermore, studies conducted via video recording, revealed that 20-60% of patients had inadvertently touched part of the eye either the ocular surface, eyelids or eyelashes while attempting to administer their eye drops [4,5] with further adverse consequences.…”

Section: Introductionmentioning

confidence: 99%